Skip to main content Skip to section navigation Skip to footer
Avalo Therapeutics, Inc. Corporate Home
  • About
    • Overview
    • Leadership
    • Board of directors
    • Contact
  • Science
    • Overview
    • IL-1β in HS
    • IL-1β in CPPD
  • Pipeline
    • Overview
    • AVTX-009 for HS
    • AVTX-009 for CPPD
  • Patients
    • Our commitment
    • Clinical trials
    • Resources
    • Access to investigational therapies
  • Investors
    • Overview
    • News, events & presentations
    • Analyst coverage
    • Stock data
    • SEC filings
    • Corporate governance
    • IR resources
  • Careers
    • Overview
    • Values
    • Benefits
    • Job openings

Press Releases

News, events & presentations

News, events & presentations

  • Press Releases
  • Events
  • Presentations
  • Email alerts
Jan 4, 2016 9:10 am EST
Cerecor Inc. to Present at Biotech Showcase 2016 in San Francisco
Dec 21, 2015 9:00 am EST
Cerecor Inc. Names Uli Hacksell, Chairman of Cerecor and Former CEO of ACADIA, as President and CEO
Dec 11, 2015 9:15 am EST
Publication Reports Human Brain Penetration and Target Engagement of Cerecor’s Oral Kappa Opioid Receptor Antagonist, CERC-501
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Contact IR
  • RSS
  • Email Alerts
  • Accessibility
    accessibility
610.254.4205
in
1500 Liberty Ridge Drive
Suite 321
Wayne, PA 19087
Avalo
PRIVACY POLICY DISCLAIMER
©2025 Avalo Therapeutics, Inc.